318 Half Day Road
About BIOLIFE4DBIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time.
Founding Partner, CEO, President and Board Member: Steven Morris
CFO: Jim Hechtman
VP and Board Member: Lisa Somlo
SCIENCE & TECHNOLOGY:
Please click here for BIOLIFE4D's science and technology.
11 articles with BIOLIFE4D
BIOLIFE4D Announces Intention to Submit Draft Registration Statement for Underwritten Public Offering of Common Stock
BIOLIFE4D Corporation today announced that it intends to submit a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission in early 2022 for a proposed underwritten public offering of its common stock.
BIOLIFE4D Names Pharmaceutical Veteran Kate Lewis as PresidentCompany’s first female executive to lead commercialization efforts of BIOLIFE4D’s live-saving 3D bioprinting technologies
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Kate Lewis as President of the company.
BIOLIFE4D CSO Dr. Ravi Birla Publishes Paper in Prestigious APL Bioengineering Scholarly JournalBirla co-published paper with Stuart K. Williams, a renowned industry figure, to highlight 3D bioprinting’s impact on cardiac failure treatment
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, announced its Chief Science Officer, Dr. Ravi Birla, has published a paper in the prestigious APL Bioengineering scholarly journal.
BIOLIFE4D Successfully 3D Bioprints a Miniature Human Heart—One Step Closer to Bioprinting Transp...
9/16/2019The miniature heart had all the structures of a full-sized heart, with four internal chambers. The company says it is as close as anyone has gotten to a fully functioning heart via 3D bioprinting.
Agreement provides access to world class academic research facilities and resources, including sophisticated imaging and instrumentation capabilities,.
BIOLIFE4D Targets High Growth Healthcare 3D Printing Market as it Readies for Regulation A+ Offering
Healthcare 3D printing market projected to reach $2.2B by 2024, driven by applications in tissue engineering and regenerative medicine; Company prepares to take investments for its pioneering 3D bioprinting technology.
Company adds renowned stem cell expert from the Texas Heart Institute to lead research as it continues development of its lifesaving heart transplant technology.
BIOLIFE4D Proceeding on Mission to Bioprint Human Hearts, Taps Regenerative Biomaterials Expert Adam W. Feinberg, Ph.D. to Lead Scientific Advisory Team
BIOLIFE4D seeks to optimize a process that will capitalize on the growing number of milestones that have been reached in the field of 3D bioprinting recently.
BIOLIFE4D Appoints Texas Heart Institute Surgeon Dr. Jeffrey Morgan Chief Medical Officer, Bolstering Leadership Team
Bioprinting startup BIOLIFE4D named accomplished thoracic and cardiac surgeon Jeffrey Morgan M.D., FACS, FACC as CMO.
BIOLIFE4D Welcomes Computational Medicine And Biomedical Engineering Expert Raimond Winslow, Ph.D. To Scientific Advisory Team
Biotech Pioneer BIOLIFE4D Submits Regulation A+ Filing With SEC For Up To $50 Million Initial Public Offering